ACTOS(R) (pioglitazone HCl) to be marketed by Takeda in Canadian Market
MISSISSAUGA, ON, Aug. 21 /CNW/ - Takeda Canada, Inc. announced that it
has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl),
an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the
discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide
agreement in 1999.
"Reacquiring the commercial rights to ACTOS is Takeda's first opportunity
to establish a commercial presence in Canada," said Daaron Dohler, general
manager at Takeda Canada. "It also underscores Takeda's ongoing efforts to
reinforce our global operations and build a stronger presence in North
ACTOS was approved by Health Canada as monotherapy to decrease insulin
resistance and blood glucose levels in patients with type 2 diabetes mellitus,
in September 2000. Takeda has taken over responsibility for ACTOS in the
Canadian market effective mid-June. The company already sells ACTOS in many
other territories, including the United States, Japan and most of Europe.
About Takeda Canada, Inc.
Based in Mississauga, Ontario, Takeda Canada, Inc. is a subsidiary of
Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in
Japan. The company currently markets an oral diabetes treatment, and seeks to
bring innovative products to patients through a pipeline that includes
compounds in development for diabetes, cardiovascular disease, oncology,
gastroenterology, rheumatology and other conditions. Takeda is committed to
striving toward better health for individuals and progress in medicine by
developing superior pharmaceutical products. Additional information about
Takeda Canada is available through its web site, www.takedacanada.com.
For further information:
For further information: MEDIA CONTACT: Laurene Redding, Takeda Canada
Inc., (905) 361-6442, firstname.lastname@example.org